Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)

被引：0
|
作者：
Fox, E. [1 ]
Wray, S. [2 ]
Shubin, R. [3 ]
Lovett-Racke, A. [4 ]
Huang, D. [5 ]
Bass, A. [6 ]
Weiss, M. [7 ]
Power, S. [7 ]
Bosco, J. [7 ]
Mok, K. [7 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Hope Neurol, Knoxville, TN USA
[3] Arcadia Neurol Ctr, Arcardia, CA USA
[4] Ohio State Univ, Dept Microbial Infect & Immun, Columbus, OH 43210 USA
[5] Mt Carmel Hlth Syst, Ctr Multiple Sclerosis, Westerville, OH USA
[6] Neurol Ctr San Antonio, San Antonio, TX USA
[7] TG Therapeut, New York, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1023
引用
收藏
页码：543 / 544
页数：2
相关论文
共 50 条
  • [21] IDEC-C2B8 anti-CD20 antibody: Results of long-term follow-up of relapsed NHL phase II trial patients
    Maloney, DG
    GrilloLopez, AJ
    Bodkin, D
    White, C
    Foon, K
    Schilder, RJ
    Neidhart, J
    Janakiraman, N
    Waldichuk, C
    Davis, T
    Dallaire, BK
    Royston, I
    Levy, R
    BLOOD, 1995, 86 (10) : 205 - 205
  • [22] Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
    Coiffier, B
    Haioun, C
    Ketterer, N
    Engert, A
    Tilly, H
    Ma, D
    Johnson, P
    Lister, A
    Feuring-Buske, M
    Radford, JA
    Capdeville, R
    Diehl, V
    Reyes, F
    BLOOD, 1998, 92 (06) : 1927 - 1932
  • [23] Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
    Sharman, Jeff P.
    Farber, Charles M.
    Mahadevan, Daruka
    Schreeder, Marshall T.
    Brooks, Heather D.
    Kolibaba, Kathryn S.
    Fanning, Suzanne R.
    Klein, Leonard M.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Greenwald, Daniel R.
    BLOOD, 2014, 124 (21)
  • [24] Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years
    Confavreux, Christian
    Li, David K.
    Freedman, Mark S.
    Truffinet, Philippe
    Benzerdjeb, Hadj
    Wang, Dazhe
    Bar-Or, Amit
    Traboulsee, Anthony L.
    Reiman, Lucy E.
    O'Connor, Paul W.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (09) : 1278 - 1289
  • [25] Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
    Kolibaba, Kathryn
    Burke, John M.
    Brooks, Heather D.
    Mahadevan, Daruka
    Melear, Jason
    Farber, Charles M.
    Fanning, Suzanne R.
    Schreeder, Marshall T.
    Boccia, Ralph V.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Sharman, Jeff P.
    BLOOD, 2015, 126 (23)
  • [26] A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.
    O'Connor, Owen A.
    Deng, Changchun
    Amengual, Jennifer Effie
    Khalil, Mazen Y.
    Schreeder, Marshall T.
    Mahadevan, Daruka
    Nikolinakos, Petros
    Sawas, Ahmed
    Zain, Jasmine M.
    Patterson, Molly
    Moon, Amber
    Pauli, Emily K.
    Cutter, Kathy
    Mackenzie, Michelle Ann
    Brotherton, Marnie
    Hodgson, Jamie
    Cooper, Christen N.
    Sportelli, Peter
    Miskin, Hari P.
    Farber, Charles Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] FINAL RESULTS OF A MULTICENTER PHASE IB SINGLE AGENT STUDY WITH THE NOVEL ANTI-CD20 MONOCLONAL ANTIBODY UBLITUXIMAB (TG-1101) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Cazin, B.
    Lepretre, S.
    Coiffier, B.
    Aurran, T.
    Cartron, G.
    Feugier, P.
    Brehar, O.
    Sadoun, A.
    Sportelli, P.
    Miskin, H.
    Ribrag, V.
    HAEMATOLOGICA, 2013, 98 : 47 - 47
  • [28] Avonex® 15-year long-term follow-up study of patients with relapsing multiple sclerosis
    Bermel, Robert A.
    Weinstock-Guttman, Bianca
    Bourdette, Dennis N.
    Rudick, Richard A.
    Zhang, Hao
    Foulds, Pamela
    MULTIPLE SCLEROSIS, 2008, 14 : S32 - S32
  • [29] Predictive value of the multiple sclerosis functional composite in relapsing-remitting Multiple Sclerosis: Results of a long-term follow-up study
    Rudick, RA
    Cutter, G
    Baier, M
    Dougherty, DS
    Weinstock-Guttman, B
    Mass, MK
    Fisher, E
    Miller, DM
    Simonian, NA
    NEUROLOGY, 2000, 54 (07) : A215 - A215
  • [30] A phase 1 trial of BCD-132, a novel anti-CD20 monoclonal antibody, in patients with remitting forms of multiple sclerosis
    Boyko, O.
    Zinkina-Orikhan, A.
    Kotov, S.
    Linkova, Y.
    Prakhova, L.
    Totolyan, N.
    Shur, S.
    Boyko, A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 740 - 741
12345